Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 7/2015

01.10.2015 | Invited Review

Neurobiological background of negative symptoms

verfasst von: Silvana Galderisi, Eleonora Merlotti, Armida Mucci

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Studies investigating neurobiological bases of negative symptoms of schizophrenia failed to provide consistent findings, possibly due to the heterogeneity of this psychopathological construct. We tried to review the findings published to date investigating neurobiological abnormalities after reducing the heterogeneity of the negative symptoms construct. The literature in electronic databases as well as citations and major articles are reviewed with respect to the phenomenology, pathology, genetics and neurobiology of schizophrenia. We searched PubMed with the keywords “negative symptoms,” “deficit schizophrenia,” “persistent negative symptoms,” “neurotransmissions,” “neuroimaging” and “genetic.” Additional articles were identified by manually checking the reference lists of the relevant publications. Publications in English were considered, and unpublished studies, conference abstracts and poster presentations were not included. Structural and functional imaging studies addressed the issue of neurobiological background of negative symptoms from several perspectives (considering them as a unitary construct, focusing on primary and/or persistent negative symptoms and, more recently, clustering them into factors), but produced discrepant findings. The examined studies provided evidence suggesting that even primary and persistent negative symptoms include different psychopathological constructs, probably reflecting the dysfunction of different neurobiological substrates. Furthermore, they suggest that complex alterations in multiple neurotransmitter systems and genetic variants might influence the expression of negative symptoms in schizophrenia. On the whole, the reviewed findings, representing the distillation of a large body of disparate data, suggest that further deconstruction of negative symptomatology into more elementary components is needed to gain insight into underlying neurobiological mechanisms.
Literatur
1.
Zurück zum Zitat Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32(2):214–219PubMedCentralPubMedCrossRef Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32(2):214–219PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Carpenter WT Jr, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145(5):578–583PubMedCrossRef Carpenter WT Jr, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145(5):578–583PubMedCrossRef
3.
Zurück zum Zitat Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Dell’Osso L, Daneluzzo E, Pini S (2002) Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 159(6):983–990PubMedCrossRef Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Dell’Osso L, Daneluzzo E, Pini S (2002) Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 159(6):983–990PubMedCrossRef
4.
Zurück zum Zitat Kirkpatrick B, Galderisi S (2008) Deficit schizophrenia: an update. World Psychiatry Off J World Psychiatr Assoc 7(3):143–147 Kirkpatrick B, Galderisi S (2008) Deficit schizophrenia: an update. World Psychiatry Off J World Psychiatr Assoc 7(3):143–147
5.
Zurück zum Zitat Galderisi S, Maj M (2009) Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry Journal Assoc Eur Psychiatr 24(8):493–500CrossRef Galderisi S, Maj M (2009) Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry Journal Assoc Eur Psychiatr 24(8):493–500CrossRef
6.
Zurück zum Zitat Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW (2007) Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 33(5):1201–1212PubMedCentralPubMedCrossRef Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW (2007) Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 33(5):1201–1212PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155(6):751–760PubMed Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155(6):751–760PubMed
8.
Zurück zum Zitat Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr (2001) A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58(2):165–171PubMedCrossRef Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr (2001) A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58(2):165–171PubMedCrossRef
9.
Zurück zum Zitat Galderisi S, Bucci P, Mucci A, Kirkpatrick B, Pini S, Rossi A, Vita A, Maj M (2013) Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res 147(1):157–162PubMedCrossRef Galderisi S, Bucci P, Mucci A, Kirkpatrick B, Pini S, Rossi A, Vita A, Maj M (2013) Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res 147(1):157–162PubMedCrossRef
11.
Zurück zum Zitat Blanchard JJ, Cohen AS (2006) The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 32(2):238–245PubMedCentralPubMedCrossRef Blanchard JJ, Cohen AS (2006) The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 32(2):238–245PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat O’Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC (2000) Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 12(1):4–15PubMedCrossRef O’Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC (2000) Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 12(1):4–15PubMedCrossRef
14.
Zurück zum Zitat Bodnar M, Malla A, Joober R, Lepage M (2008) Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry 193(4):297–304PubMedCrossRef Bodnar M, Malla A, Joober R, Lepage M (2008) Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry 193(4):297–304PubMedCrossRef
15.
Zurück zum Zitat Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12:224PubMedCentralPubMedCrossRef Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12:224PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS, Eufest Study G (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 23(3):196–204PubMedCrossRef Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS, Eufest Study G (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 23(3):196–204PubMedCrossRef
17.
Zurück zum Zitat Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR (2011) The brief negative symptom scale: psychometric properties. Schizophr Bull 37(2):300–305PubMedCentralPubMedCrossRef Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR (2011) The brief negative symptom scale: psychometric properties. Schizophr Bull 37(2):300–305PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Strauss GP, Hong LE, Gold JM, Buchanan RW, McMahon RP, Keller WR, Fischer BA, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B (2012) Factor structure of the Brief Negative Symptom Scale. Schizophr Res 142(1–3):96–98PubMedCentralPubMedCrossRef Strauss GP, Hong LE, Gold JM, Buchanan RW, McMahon RP, Keller WR, Fischer BA, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B (2012) Factor structure of the Brief Negative Symptom Scale. Schizophr Res 142(1–3):96–98PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32(2):274–278PubMedCentralPubMedCrossRef Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32(2):274–278PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Nakaya M, Ohmori K (2008) A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res 158(2):256–259PubMedCrossRef Nakaya M, Ohmori K (2008) A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res 158(2):256–259PubMedCrossRef
21.
Zurück zum Zitat Messinger JW, Tremeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D (2011) Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 31(1):161–168PubMedCentralPubMedCrossRef Messinger JW, Tremeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D (2011) Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 31(1):161–168PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF, Carpenter WT Jr (2013) Deconstructing negative symptoms of schizophrenia: avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome. Psychiatry Res 47(6):783–790CrossRef Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF, Carpenter WT Jr (2013) Deconstructing negative symptoms of schizophrenia: avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome. Psychiatry Res 47(6):783–790CrossRef
23.
Zurück zum Zitat Kemali D, Maj M, Galderisi S, Salvati A, Starace F, Valente A, Pirozzi R (1987) Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder. Psychiatry Res 21(2):137–149PubMedCrossRef Kemali D, Maj M, Galderisi S, Salvati A, Starace F, Valente A, Pirozzi R (1987) Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder. Psychiatry Res 21(2):137–149PubMedCrossRef
24.
Zurück zum Zitat Andreasen NC, Swayze VW, Flaum M, Yates WR, Arndt S, McChesney C (1990) Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness. Arch Gen Psychiatry 47(11):1008–1015PubMedCrossRef Andreasen NC, Swayze VW, Flaum M, Yates WR, Arndt S, McChesney C (1990) Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness. Arch Gen Psychiatry 47(11):1008–1015PubMedCrossRef
25.
Zurück zum Zitat Johnstone EC, Bruton CJ, Crow TJ, Frith CD, Owens DG (1994) Clinical correlates of postmortem brain changes in schizophrenia: decreased brain weight and length correlate with indices of early impairment. J Neurol Neurosurg Psychiatry 57(4):474–479PubMedCentralPubMedCrossRef Johnstone EC, Bruton CJ, Crow TJ, Frith CD, Owens DG (1994) Clinical correlates of postmortem brain changes in schizophrenia: decreased brain weight and length correlate with indices of early impairment. J Neurol Neurosurg Psychiatry 57(4):474–479PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Saijo T, Abe T, Someya Y, Sassa T, Sudo Y, Suhara T, Shuno T, Asai K, Okubo Y (2001) Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study. Psychiatry Clin Neurosci 55(1):41–47PubMedCrossRef Saijo T, Abe T, Someya Y, Sassa T, Sudo Y, Suhara T, Shuno T, Asai K, Okubo Y (2001) Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study. Psychiatry Clin Neurosci 55(1):41–47PubMedCrossRef
27.
Zurück zum Zitat Keilp JG, Sweeney JA, Jacobsen P, Solomon C, St Louis L, Deck M, Frances A, Mann JJ (1988) Cognitive impairment in schizophrenia: specific relations to ventricular size and negative symptomatology. Biol Psychiatry 24(1):47–55PubMedCrossRef Keilp JG, Sweeney JA, Jacobsen P, Solomon C, St Louis L, Deck M, Frances A, Mann JJ (1988) Cognitive impairment in schizophrenia: specific relations to ventricular size and negative symptomatology. Biol Psychiatry 24(1):47–55PubMedCrossRef
28.
Zurück zum Zitat Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM, Jernigan TL (1988) Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Arch Gen Psychiatry 45(7):633–640PubMedCrossRef Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM, Jernigan TL (1988) Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Arch Gen Psychiatry 45(7):633–640PubMedCrossRef
29.
Zurück zum Zitat Bishop RJ, Golden CJ, MacInnes WD, Chu CC, Ruedrich SL, Wilson J (1983) The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia. Psychiatry Res 9(3):225–231PubMedCrossRef Bishop RJ, Golden CJ, MacInnes WD, Chu CC, Ruedrich SL, Wilson J (1983) The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia. Psychiatry Res 9(3):225–231PubMedCrossRef
30.
Zurück zum Zitat Luchins DJ, Lewine RR, Meltzer HY (1984) Lateral ventricular size, psychopathology, and medication response in the psychoses. Biol Psychiatry 19(1):29–44PubMed Luchins DJ, Lewine RR, Meltzer HY (1984) Lateral ventricular size, psychopathology, and medication response in the psychoses. Biol Psychiatry 19(1):29–44PubMed
31.
Zurück zum Zitat Andreasen NC (1989) Neural mechanisms of negative symptoms. Br J Psychiatry 7:93–98 Andreasen NC (1989) Neural mechanisms of negative symptoms. Br J Psychiatry 7:93–98
32.
Zurück zum Zitat Berman KF, Illowsky BP, Weinberger DR (1988) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity. Arch Gen Psychiatry 45(7):616–622PubMedCrossRef Berman KF, Illowsky BP, Weinberger DR (1988) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity. Arch Gen Psychiatry 45(7):616–622PubMedCrossRef
33.
Zurück zum Zitat Weinberger DR, Berman KF (1988) Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 14(2):157–168PubMedCrossRef Weinberger DR, Berman KF (1988) Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 14(2):157–168PubMedCrossRef
34.
Zurück zum Zitat Goff DC, Evins AE (1998) Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 6(2):59–77PubMedCrossRef Goff DC, Evins AE (1998) Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 6(2):59–77PubMedCrossRef
35.
Zurück zum Zitat Kirkpatrick B, Buchanan RW (1990) The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 178(9):545–555PubMedCrossRef Kirkpatrick B, Buchanan RW (1990) The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 178(9):545–555PubMedCrossRef
36.
Zurück zum Zitat Goghari VM, Sponheim SR, MacDonald AW 3rd (2010) The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 34(3):468–486PubMedCentralPubMedCrossRef Goghari VM, Sponheim SR, MacDonald AW 3rd (2010) The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 34(3):468–486PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Andreasen N, Nasrallah HA, Dunn V, Olson SC, Grove WM, Ehrhardt JC, Coffman JA, Crossett JH (1986) Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study. Arch Gen Psychiatry 43(2):136–144PubMedCrossRef Andreasen N, Nasrallah HA, Dunn V, Olson SC, Grove WM, Ehrhardt JC, Coffman JA, Crossett JH (1986) Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study. Arch Gen Psychiatry 43(2):136–144PubMedCrossRef
38.
Zurück zum Zitat DeMyer MK, Gilmor RL, Hendrie HC, DeMyer WE, Augustyn GT, Jackson RK (1988) Magnetic resonance brain images in schizophrenic and normal subjects: influence of diagnosis and education. Schizophr Bull 14(1):21–37PubMedCrossRef DeMyer MK, Gilmor RL, Hendrie HC, DeMyer WE, Augustyn GT, Jackson RK (1988) Magnetic resonance brain images in schizophrenic and normal subjects: influence of diagnosis and education. Schizophr Bull 14(1):21–37PubMedCrossRef
39.
Zurück zum Zitat Raine A, Lencz T, Reynolds GP, Harrison G, Sheard C, Medley I, Reynolds LM, Cooper JE (1992) An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res 45(2):123–137PubMedCrossRef Raine A, Lencz T, Reynolds GP, Harrison G, Sheard C, Medley I, Reynolds LM, Cooper JE (1992) An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res 45(2):123–137PubMedCrossRef
40.
Zurück zum Zitat Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE (1995) Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry 52(12):1061–1070PubMedCrossRef Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE (1995) Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry 52(12):1061–1070PubMedCrossRef
41.
Zurück zum Zitat Baare WF, Hulshoff Pol HE, Hijman R, Mali WP, Viergever MA, Kahn RS (1999) Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol Psychiatry 45(12):1597–1605PubMedCrossRef Baare WF, Hulshoff Pol HE, Hijman R, Mali WP, Viergever MA, Kahn RS (1999) Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol Psychiatry 45(12):1597–1605PubMedCrossRef
42.
Zurück zum Zitat Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, Levitt JJ, O’Donnell BF, Kikinis R, Jolesz FA, McCarley RW (2001) Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res 108(2):65–78PubMedCentralPubMedCrossRef Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, Levitt JJ, O’Donnell BF, Kikinis R, Jolesz FA, McCarley RW (2001) Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res 108(2):65–78PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Hazlett EA, Buchsbaum MS, Haznedar MM, Newmark R, Goldstein KE, Zelmanova Y, Glanton CF, Torosjan Y, New AS, Lo JN, Mitropoulou V, Siever LJ (2008) Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr Res 101(1–3):111–123PubMedCentralPubMedCrossRef Hazlett EA, Buchsbaum MS, Haznedar MM, Newmark R, Goldstein KE, Zelmanova Y, Glanton CF, Torosjan Y, New AS, Lo JN, Mitropoulou V, Siever LJ (2008) Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr Res 101(1–3):111–123PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Koutsouleris N, Gaser C, Jager M, Bottlender R, Frodl T, Holzinger S, Schmitt GJ, Zetzsche T, Burgermeister B, Scheuerecker J, Born C, Reiser M, Moller HJ, Meisenzahl EM (2008) Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. NeuroImage 39(4):1600–1612PubMedCrossRef Koutsouleris N, Gaser C, Jager M, Bottlender R, Frodl T, Holzinger S, Schmitt GJ, Zetzsche T, Burgermeister B, Scheuerecker J, Born C, Reiser M, Moller HJ, Meisenzahl EM (2008) Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. NeuroImage 39(4):1600–1612PubMedCrossRef
45.
Zurück zum Zitat Nesvag R, Saetre P, Lawyer G, Jonsson EG, Agartz I (2009) The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33(3):482–490PubMedCrossRef Nesvag R, Saetre P, Lawyer G, Jonsson EG, Agartz I (2009) The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33(3):482–490PubMedCrossRef
46.
Zurück zum Zitat Lacerda AL, Hardan AY, Yorbik O, Vemulapalli M, Prasad KM, Keshavan MS (2007) Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology. Prog Neuropsychopharmacol Biol Psychiatry 31(2):510–516PubMedCrossRef Lacerda AL, Hardan AY, Yorbik O, Vemulapalli M, Prasad KM, Keshavan MS (2007) Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology. Prog Neuropsychopharmacol Biol Psychiatry 31(2):510–516PubMedCrossRef
47.
Zurück zum Zitat Young AH, Blackwood DH, Roxborough H, McQueen JK, Martin MJ, Kean D (1991) A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms. Br J Psychiatry 158:158–164PubMedCrossRef Young AH, Blackwood DH, Roxborough H, McQueen JK, Martin MJ, Kean D (1991) A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms. Br J Psychiatry 158:158–164PubMedCrossRef
48.
Zurück zum Zitat Zetzsche T, Preuss UW, Frodl T, Leinsinger G, Born C, Reiser M, Hegerl U, Moller HJ, Meisenzahl EM (2008) White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. Eur Arch Psychiatry Clin Neurosci 258(5):278–284PubMedCrossRef Zetzsche T, Preuss UW, Frodl T, Leinsinger G, Born C, Reiser M, Hegerl U, Moller HJ, Meisenzahl EM (2008) White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. Eur Arch Psychiatry Clin Neurosci 258(5):278–284PubMedCrossRef
49.
Zurück zum Zitat Nestor PG, Onitsuka T, Gurrera RJ, Niznikiewicz M, Frumin M, Shenton ME, McCarley RW (2007) Dissociable contributions of MRI volume reductions of superior temporal and fusiform gyri to symptoms and neuropsychology in schizophrenia. Schizophr Res 91(1–3):103–106PubMedCentralPubMedCrossRef Nestor PG, Onitsuka T, Gurrera RJ, Niznikiewicz M, Frumin M, Shenton ME, McCarley RW (2007) Dissociable contributions of MRI volume reductions of superior temporal and fusiform gyri to symptoms and neuropsychology in schizophrenia. Schizophr Res 91(1–3):103–106PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Tibbo P, Nopoulos P, Arndt S, Andreasen NC (1998) Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry 44(6):405–412PubMedCrossRef Tibbo P, Nopoulos P, Arndt S, Andreasen NC (1998) Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry 44(6):405–412PubMedCrossRef
51.
Zurück zum Zitat Kim JJ, Crespo-Facorro B, Andreasen NC, O’Leary DS, Magnotta V, Nopoulos P (2003) Morphology of the lateral superior temporal gyrus in neuroleptic naive patients with schizophrenia: relationship to symptoms. Schizophr Res 60(2–3):173–181PubMed Kim JJ, Crespo-Facorro B, Andreasen NC, O’Leary DS, Magnotta V, Nopoulos P (2003) Morphology of the lateral superior temporal gyrus in neuroleptic naive patients with schizophrenia: relationship to symptoms. Schizophr Res 60(2–3):173–181PubMed
52.
Zurück zum Zitat Szendi I, Kiss M, Racsmany M, Boda K, Cimmer C, Voros E, Kovacs ZA, Szekeres G, Galsi G, Pleh C, Csernay L, Janka Z (2006) Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. Psychiatry Res 147(1):47–55PubMedCrossRef Szendi I, Kiss M, Racsmany M, Boda K, Cimmer C, Voros E, Kovacs ZA, Szekeres G, Galsi G, Pleh C, Csernay L, Janka Z (2006) Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. Psychiatry Res 147(1):47–55PubMedCrossRef
53.
Zurück zum Zitat Pakkenberg B (1987) Post-mortem study of chronic schizophrenic brains. Br J Psychiatry 151:744–752PubMedCrossRef Pakkenberg B (1987) Post-mortem study of chronic schizophrenic brains. Br J Psychiatry 151:744–752PubMedCrossRef
54.
Zurück zum Zitat Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL (1998) Postmortem studies in schizophrenia. Schizophr Bull 24(3):325–341PubMedCrossRef Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL (1998) Postmortem studies in schizophrenia. Schizophr Bull 24(3):325–341PubMedCrossRef
55.
Zurück zum Zitat Kawasaki Y, Maeda Y, Suzuki M, Urata K, Higashima M, Kiba K, Yamaguchi N, Matsuda H, Hisada K (1993) SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr Res 10(2):109–116PubMedCrossRef Kawasaki Y, Maeda Y, Suzuki M, Urata K, Higashima M, Kiba K, Yamaguchi N, Matsuda H, Hisada K (1993) SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr Res 10(2):109–116PubMedCrossRef
56.
Zurück zum Zitat Ebmeier KP, Blackwood DH, Murray C, Souza V, Walker M, Dougall N, Moffoot AP, O’Carroll RE, Goodwin GM (1993) Single-photon emission computed tomography with 99 mTc-exametazime in unmedicated schizophrenic patients. Biol Psychiatry 33(7):487–495PubMedCrossRef Ebmeier KP, Blackwood DH, Murray C, Souza V, Walker M, Dougall N, Moffoot AP, O’Carroll RE, Goodwin GM (1993) Single-photon emission computed tomography with 99 mTc-exametazime in unmedicated schizophrenic patients. Biol Psychiatry 33(7):487–495PubMedCrossRef
57.
Zurück zum Zitat Klemm E, Danos P, Grunwald F, Kasper S, Moller HJ, Biersack HJ (1996) Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression–a study with single photon emission computed tomography. Psychiatry Res 68(1):1–10PubMedCrossRef Klemm E, Danos P, Grunwald F, Kasper S, Moller HJ, Biersack HJ (1996) Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression–a study with single photon emission computed tomography. Psychiatry Res 68(1):1–10PubMedCrossRef
58.
Zurück zum Zitat Schroder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, Wu J, Potkin SG (1996) Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res 19(1):41–53PubMedCrossRef Schroder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, Wu J, Potkin SG (1996) Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res 19(1):41–53PubMedCrossRef
59.
Zurück zum Zitat Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C, Kaiser HJ, Steinmeyer EM, Sass H, Buell U (1997) Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med 38(2):181–188PubMed Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C, Kaiser HJ, Steinmeyer EM, Sass H, Buell U (1997) Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med 38(2):181–188PubMed
60.
Zurück zum Zitat Erkwoh R, Sabri O, Steinmeyer EM, Bull U, Sass H (1997) Psychopathological and SPECT findings in never-treated schizophrenia. Acta Psychiatr Scand 96(1):51–57PubMedCrossRef Erkwoh R, Sabri O, Steinmeyer EM, Bull U, Sass H (1997) Psychopathological and SPECT findings in never-treated schizophrenia. Acta Psychiatr Scand 96(1):51–57PubMedCrossRef
61.
Zurück zum Zitat Heckers S, Goff D, Schacter DL, Savage CR, Fischman AJ, Alpert NM, Rauch SL (1999) Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatry 56(12):1117–1123PubMedCrossRef Heckers S, Goff D, Schacter DL, Savage CR, Fischman AJ, Alpert NM, Rauch SL (1999) Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatry 56(12):1117–1123PubMedCrossRef
62.
Zurück zum Zitat Andreasen NC, Rezai K, Alliger R, Swayze VW 2nd, Flaum M, Kirchner P, Cohen G, O’Leary DS (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49(12):943–958PubMedCrossRef Andreasen NC, Rezai K, Alliger R, Swayze VW 2nd, Flaum M, Kirchner P, Cohen G, O’Leary DS (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49(12):943–958PubMedCrossRef
63.
Zurück zum Zitat Siegel BV Jr, Buchsbaum MS, Bunney WE Jr, Gottschalk LA, Haier RJ, Lohr JB, Lottenberg S, Najafi A, Nuechterlein KH, Potkin SG et al (1993) Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 150(9):1325–1336PubMedCrossRef Siegel BV Jr, Buchsbaum MS, Bunney WE Jr, Gottschalk LA, Haier RJ, Lohr JB, Lottenberg S, Najafi A, Nuechterlein KH, Potkin SG et al (1993) Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 150(9):1325–1336PubMedCrossRef
64.
Zurück zum Zitat Erkwoh R, Sabri O, Willmes K, Steinmeyer EM, Bull U, Sass H (1999) Active and remitted schizophrenia: psychopathological and regional cerebral blood flow findings. Psychiatry Res 90(1):17–30PubMedCrossRef Erkwoh R, Sabri O, Willmes K, Steinmeyer EM, Bull U, Sass H (1999) Active and remitted schizophrenia: psychopathological and regional cerebral blood flow findings. Psychiatry Res 90(1):17–30PubMedCrossRef
65.
Zurück zum Zitat Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49(12):959–965PubMedCrossRef Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49(12):959–965PubMedCrossRef
66.
Zurück zum Zitat Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49(7):522–530PubMedCrossRef Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49(7):522–530PubMedCrossRef
67.
Zurück zum Zitat Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH (2002) A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry 159(2):227–237PubMedCrossRef Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH (2002) A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry 159(2):227–237PubMedCrossRef
68.
Zurück zum Zitat Vita A, Bressi S, Perani D, Invernizzi G, Giobbio GM, Dieci M, Garbarini M, Del Sole A, Fazio F (1995) High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am J Psychiatry 152(6):876–882PubMedCrossRef Vita A, Bressi S, Perani D, Invernizzi G, Giobbio GM, Dieci M, Garbarini M, Del Sole A, Fazio F (1995) High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am J Psychiatry 152(6):876–882PubMedCrossRef
69.
Zurück zum Zitat Min SK, An SK, Jon DI, Lee JD (1999) Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. Psychiatry Res 90(3):159–168PubMedCrossRef Min SK, An SK, Jon DI, Lee JD (1999) Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. Psychiatry Res 90(3):159–168PubMedCrossRef
70.
Zurück zum Zitat Yuasa S, Kurachi M, Suzuki M, Kadono Y, Matsui M, Saitoh O, Seto H (1995) Clinical symptoms and regional cerebral blood flow in schizophrenia. Eur Arch Psychiatry Clin Neurosci 246(1):7–12PubMedCrossRef Yuasa S, Kurachi M, Suzuki M, Kadono Y, Matsui M, Saitoh O, Seto H (1995) Clinical symptoms and regional cerebral blood flow in schizophrenia. Eur Arch Psychiatry Clin Neurosci 246(1):7–12PubMedCrossRef
71.
Zurück zum Zitat Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M et al (1995) Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 52(8):657–667PubMedCrossRef Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M et al (1995) Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 52(8):657–667PubMedCrossRef
72.
Zurück zum Zitat Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H, Kapur S, Glenthoj B (2012) Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 69(12):1195–1204PubMedCrossRef Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H, Kapur S, Glenthoj B (2012) Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 69(12):1195–1204PubMedCrossRef
73.
Zurück zum Zitat Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 187(2):222–228PubMedCrossRef Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 187(2):222–228PubMedCrossRef
74.
Zurück zum Zitat Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29(2):409–416PubMedCrossRef Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29(2):409–416PubMedCrossRef
75.
Zurück zum Zitat Schlagenhauf F, Sterzer P, Schmack K, Ballmaier M, Rapp M, Wrase J, Juckel G, Gallinat J, Heinz A (2009) Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 65(12):1032–1039PubMedCrossRef Schlagenhauf F, Sterzer P, Schmack K, Ballmaier M, Rapp M, Wrase J, Juckel G, Gallinat J, Heinz A (2009) Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 65(12):1032–1039PubMedCrossRef
76.
Zurück zum Zitat Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthoj B (2012) Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol Psychiatry 71(10):898–905PubMedCrossRef Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthoj B (2012) Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol Psychiatry 71(10):898–905PubMedCrossRef
77.
Zurück zum Zitat Waltz JA, Schweitzer JB, Ross TJ, Kurup PK, Salmeron BJ, Rose EJ, Gold JM, Stein EA (2010) Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology 35(12):2427–2439PubMedCentralPubMedCrossRef Waltz JA, Schweitzer JB, Ross TJ, Kurup PK, Salmeron BJ, Rose EJ, Gold JM, Stein EA (2010) Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology 35(12):2427–2439PubMedCentralPubMedCrossRef
78.
Zurück zum Zitat Walter H, Kammerer H, Frasch K, Spitzer M, Abler B (2009) Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology 206(1):121–132PubMedCrossRef Walter H, Kammerer H, Frasch K, Spitzer M, Abler B (2009) Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology 206(1):121–132PubMedCrossRef
79.
Zurück zum Zitat Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A (2008) Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology 196(4):673–684PubMedCrossRef Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A (2008) Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology 196(4):673–684PubMedCrossRef
80.
Zurück zum Zitat Simon JJ, Biller A, Walther S, Roesch-Ely D, Stippich C, Weisbrod M, Kaiser S (2010) Neural correlates of reward processing in schizophrenia relationship to apathy and depression. Schizophr Res 118(1–3):154–161PubMedCrossRef Simon JJ, Biller A, Walther S, Roesch-Ely D, Stippich C, Weisbrod M, Kaiser S (2010) Neural correlates of reward processing in schizophrenia relationship to apathy and depression. Schizophr Res 118(1–3):154–161PubMedCrossRef
81.
Zurück zum Zitat Esslinger C, Englisch S, Inta D, Rausch F, Schirmbeck F, Mier D, Kirsch P, Meyer-Lindenberg A, Zink M (2012) Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res 140(1–3):114–121PubMedCrossRef Esslinger C, Englisch S, Inta D, Rausch F, Schirmbeck F, Mier D, Kirsch P, Meyer-Lindenberg A, Zink M (2012) Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res 140(1–3):114–121PubMedCrossRef
83.
Zurück zum Zitat Kring AM, Elis O (2013) Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol 9:409–433PubMedCrossRef Kring AM, Elis O (2013) Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol 9:409–433PubMedCrossRef
84.
Zurück zum Zitat Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC (1994) Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry 151(3):343–350PubMedCrossRef Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC (1994) Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry 151(3):343–350PubMedCrossRef
85.
Zurück zum Zitat Quarantelli M, Larobina M, Volpe U, Amati G, Tedeschi E, Ciarmiello A, Brunetti A, Galderisi S, Alfano B (2002) Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. NeuroImage 17(1):373–384PubMedCrossRef Quarantelli M, Larobina M, Volpe U, Amati G, Tedeschi E, Ciarmiello A, Brunetti A, Galderisi S, Alfano B (2002) Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. NeuroImage 17(1):373–384PubMedCrossRef
86.
Zurück zum Zitat Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Pini S, Cassano P, Daneluzzo E, De Peri L, Stratta P, Brunetti A, Maj M (2008) Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull 34(2):393–401PubMedCentralPubMedCrossRef Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Pini S, Cassano P, Daneluzzo E, De Peri L, Stratta P, Brunetti A, Maj M (2008) Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull 34(2):393–401PubMedCentralPubMedCrossRef
87.
Zurück zum Zitat Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K, Fukuda R, Ron M, Toone B (2001) Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 158(2):234–243PubMedCrossRef Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K, Fukuda R, Ron M, Toone B (2001) Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 158(2):234–243PubMedCrossRef
88.
Zurück zum Zitat Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW (2008) Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res 162(2):91–100PubMedCrossRef Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW (2008) Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res 162(2):91–100PubMedCrossRef
89.
Zurück zum Zitat Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT Jr (1993) Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 150(1):59–65PubMedCrossRef Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT Jr (1993) Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 150(1):59–65PubMedCrossRef
90.
Zurück zum Zitat Volpe U, Mucci A, Quarantelli M, Galderisi S, Maj M (2012) Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 37(2):264–269PubMedCrossRef Volpe U, Mucci A, Quarantelli M, Galderisi S, Maj M (2012) Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 37(2):264–269PubMedCrossRef
91.
Zurück zum Zitat Fisher DJ, Labelle A, Knott VJ (2012) Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr Res 139(1–3):237–245PubMedCrossRef Fisher DJ, Labelle A, Knott VJ (2012) Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr Res 139(1–3):237–245PubMedCrossRef
92.
Zurück zum Zitat Gur RE, Jaggi JL, Shtasel DL, Ragland JD, Gur RC (1994) Cerebral blood flow in schizophrenia: effects of memory processing on regional activation. Biol Psychiatry 35(1):3–15PubMedCrossRef Gur RE, Jaggi JL, Shtasel DL, Ragland JD, Gur RC (1994) Cerebral blood flow in schizophrenia: effects of memory processing on regional activation. Biol Psychiatry 35(1):3–15PubMedCrossRef
93.
Zurück zum Zitat Mozley PD, Gur RE, Resnick SM, Shtasel DL, Richards J, Kohn M, Grossman R, Herman G, Gur RC (1994) Magnetic resonance imaging in schizophrenia: relationship with clinical measures. Schizophr Res 12(3):195–203PubMedCrossRef Mozley PD, Gur RE, Resnick SM, Shtasel DL, Richards J, Kohn M, Grossman R, Herman G, Gur RC (1994) Magnetic resonance imaging in schizophrenia: relationship with clinical measures. Schizophr Res 12(3):195–203PubMedCrossRef
94.
Zurück zum Zitat Cascella NG, Fieldstone SC, Rao VA, Pearlson GD, Sawa A, Schretlen DJ (2010) Gray-matter abnormalities in deficit schizophrenia. Schizophr Res 120(1–3):63–70PubMedCrossRef Cascella NG, Fieldstone SC, Rao VA, Pearlson GD, Sawa A, Schretlen DJ (2010) Gray-matter abnormalities in deficit schizophrenia. Schizophr Res 120(1–3):63–70PubMedCrossRef
95.
Zurück zum Zitat Takayanagi M, Wentz J, Takayanagi Y, Schretlen DJ, Ceyhan E, Wang L, Suzuki M, Sawa A, Barta PE, Ratnanather JT, Cascella NG (2013) Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. Schizophr Res 150(2–3):484–490PubMedCentralPubMedCrossRef Takayanagi M, Wentz J, Takayanagi Y, Schretlen DJ, Ceyhan E, Wang L, Suzuki M, Sawa A, Barta PE, Ratnanather JT, Cascella NG (2013) Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. Schizophr Res 150(2–3):484–490PubMedCentralPubMedCrossRef
96.
Zurück zum Zitat Ozdemir HI, Eker MC, Zengin B, Yilmaz DA, Isman Haznedaroglu D, Cinar C, Kitis O, Akay A, Gonul AS (2012) Gray matter changes in patients with deficit schizophrenia and non-deficit schizophrenia. Turk Psikiyatri Derg 23(4):237–246PubMed Ozdemir HI, Eker MC, Zengin B, Yilmaz DA, Isman Haznedaroglu D, Cinar C, Kitis O, Akay A, Gonul AS (2012) Gray matter changes in patients with deficit schizophrenia and non-deficit schizophrenia. Turk Psikiyatri Derg 23(4):237–246PubMed
97.
Zurück zum Zitat Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW (2009) White matter alterations in deficit schizophrenia. Neuropsychopharmacology 34(6):1514–1522PubMedCentralPubMedCrossRef Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW (2009) White matter alterations in deficit schizophrenia. Neuropsychopharmacology 34(6):1514–1522PubMedCentralPubMedCrossRef
98.
Zurück zum Zitat Kitis O, Ozalay O, Zengin EB, Haznedaroglu D, Eker MC, Yalvac D, Oguz K, Coburn K, Gonul AS (2012) Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. Psychiatry Clin Neurosci 66(1):34–43PubMedCrossRef Kitis O, Ozalay O, Zengin EB, Haznedaroglu D, Eker MC, Yalvac D, Oguz K, Coburn K, Gonul AS (2012) Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. Psychiatry Clin Neurosci 66(1):34–43PubMedCrossRef
99.
Zurück zum Zitat Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH (2013) Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA psychiatry 70(5):472–480PubMedCrossRef Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH (2013) Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA psychiatry 70(5):472–480PubMedCrossRef
100.
Zurück zum Zitat Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr (2001) Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 158(11):1797–1808PubMedCrossRef Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr (2001) Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 158(11):1797–1808PubMedCrossRef
101.
Zurück zum Zitat Vaiva G, Cottencin O, Llorca PM, Devos P, Dupont S, Mazas O, Rascle C, Thomas P, Steinling M, Goudemand M (2002) Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 26(3):481–485PubMedCrossRef Vaiva G, Cottencin O, Llorca PM, Devos P, Dupont S, Mazas O, Rascle C, Thomas P, Steinling M, Goudemand M (2002) Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 26(3):481–485PubMedCrossRef
102.
Zurück zum Zitat Gonul AS, Kula M, Esel E, Tutus A, Sofuoglu S (2003) A Tc-99 m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res 123(3):199–205PubMedCrossRef Gonul AS, Kula M, Esel E, Tutus A, Sofuoglu S (2003) A Tc-99 m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res 123(3):199–205PubMedCrossRef
103.
Zurück zum Zitat Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M (2013) Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophr Res 143(2–3):246–252PubMedCrossRef Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M (2013) Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophr Res 143(2–3):246–252PubMedCrossRef
104.
Zurück zum Zitat Mucci A, Dima D, Soricelli A, Volpe U, Bucci P, Frangou S, Prinster A, Salvatore M, Galderisi S, Maj M (2015) Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychol Med 12:1–14 Mucci A, Dima D, Soricelli A, Volpe U, Bucci P, Frangou S, Prinster A, Salvatore M, Galderisi S, Maj M (2015) Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychol Med 12:1–14
105.
Zurück zum Zitat Castellon SA, Asarnow RF, Goldstein MJ, Marder SR (1994) Persisting negative symptoms and information-processing deficits in schizophrenia: implications for subtyping. Psychiatry Res 54(1):59–69PubMedCrossRef Castellon SA, Asarnow RF, Goldstein MJ, Marder SR (1994) Persisting negative symptoms and information-processing deficits in schizophrenia: implications for subtyping. Psychiatry Res 54(1):59–69PubMedCrossRef
106.
Zurück zum Zitat Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, Goldman M (2000) Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45(3):191–201PubMedCrossRef Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, Goldman M (2000) Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45(3):191–201PubMedCrossRef
107.
Zurück zum Zitat Mancevski B, Keilp J, Kurzon M, Berman RM, Ortakov V, Harkavy-Friedman J, Rosoklija G, Dwork AJ (2007) Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology 40(2):83–92PubMedCrossRef Mancevski B, Keilp J, Kurzon M, Berman RM, Ortakov V, Harkavy-Friedman J, Rosoklija G, Dwork AJ (2007) Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology 40(2):83–92PubMedCrossRef
108.
Zurück zum Zitat Hovington CL, Lepage M (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother 12(1):53–69PubMedCrossRef Hovington CL, Lepage M (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother 12(1):53–69PubMedCrossRef
109.
Zurück zum Zitat Benoit A, Bodnar M, Malla AK, Joober R, Lepage M (2012) The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study. Front Psychiatry 3:42PubMedCentralPubMedCrossRef Benoit A, Bodnar M, Malla AK, Joober R, Lepage M (2012) The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study. Front Psychiatry 3:42PubMedCentralPubMedCrossRef
110.
Zurück zum Zitat Fahim C, Stip E, Mancini-Marie A, Mensour B, Boulay LJ, Leroux JM, Beaudoin G, Bourgouin P, Beauregard M (2005) Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res 140(1):1–15PubMedCrossRef Fahim C, Stip E, Mancini-Marie A, Mensour B, Boulay LJ, Leroux JM, Beaudoin G, Bourgouin P, Beauregard M (2005) Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res 140(1):1–15PubMedCrossRef
111.
Zurück zum Zitat Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, Wolf DH, Bilker WB, Gur RC (2007) Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry 64(12):1356–1366PubMedCrossRef Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, Wolf DH, Bilker WB, Gur RC (2007) Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry 64(12):1356–1366PubMedCrossRef
112.
Zurück zum Zitat Lepage M, Sergerie K, Benoit A, Czechowska Y, Dickie E, Armony JL (2011) Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates. Psychol Med 41(9):1833–1844PubMedCrossRef Lepage M, Sergerie K, Benoit A, Czechowska Y, Dickie E, Armony JL (2011) Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates. Psychol Med 41(9):1833–1844PubMedCrossRef
113.
114.
Zurück zum Zitat Burbridge JA, Barch DM (2007) Anhedonia and the experience of emotion in individuals with schizophrenia. J Abnorm Psychol 116(1):30–42PubMedCrossRef Burbridge JA, Barch DM (2007) Anhedonia and the experience of emotion in individuals with schizophrenia. J Abnorm Psychol 116(1):30–42PubMedCrossRef
115.
Zurück zum Zitat Gard DE, Kring AM, Gard MG, Horan WP, Green MF (2007) Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 93(1–3):253–260PubMedCentralPubMedCrossRef Gard DE, Kring AM, Gard MG, Horan WP, Green MF (2007) Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 93(1–3):253–260PubMedCentralPubMedCrossRef
116.
Zurück zum Zitat Herbener ES, Song W, Khine TT, Sweeney JA (2008) What aspects of emotional functioning are impaired in schizophrenia? Schizophr Res 98(1–3):239–246PubMedCentralPubMedCrossRef Herbener ES, Song W, Khine TT, Sweeney JA (2008) What aspects of emotional functioning are impaired in schizophrenia? Schizophr Res 98(1–3):239–246PubMedCentralPubMedCrossRef
117.
Zurück zum Zitat Barch DM, Dowd EC (2010) Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 36(5):919–934PubMedCentralPubMedCrossRef Barch DM, Dowd EC (2010) Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 36(5):919–934PubMedCentralPubMedCrossRef
118.
119.
Zurück zum Zitat Simpson EH, Waltz JA, Kellendonk C, Balsam PD (2012) Schizophrenia in translation: dissecting motivation in schizophrenia and rodents. Schizophr Bull 38(6):1111–1117PubMedCentralPubMedCrossRef Simpson EH, Waltz JA, Kellendonk C, Balsam PD (2012) Schizophrenia in translation: dissecting motivation in schizophrenia and rodents. Schizophr Bull 38(6):1111–1117PubMedCentralPubMedCrossRef
120.
Zurück zum Zitat Castner SA, Goldman-Rakic PS (1999) Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 1:10–28CrossRef Castner SA, Goldman-Rakic PS (1999) Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 1:10–28CrossRef
121.
Zurück zum Zitat Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97(14):8104–8109PubMedCentralPubMedCrossRef Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97(14):8104–8109PubMedCentralPubMedCrossRef
122.
Zurück zum Zitat Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148(11):1474–1486PubMedCrossRef Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148(11):1474–1486PubMedCrossRef
123.
Zurück zum Zitat Seeman P, Van Tol HH (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15(7):264–270PubMedCrossRef Seeman P, Van Tol HH (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15(7):264–270PubMedCrossRef
124.
Zurück zum Zitat Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T (1999) Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 96(23):13432–13437PubMedCentralPubMedCrossRef Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T (1999) Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 96(23):13432–13437PubMedCentralPubMedCrossRef
125.
Zurück zum Zitat Heinz A (2000) The dopamine hypothesis of schizophrenia. New findings for an old theory. Nervenarzt 71(1):54–57PubMedCrossRef Heinz A (2000) The dopamine hypothesis of schizophrenia. New findings for an old theory. Nervenarzt 71(1):54–57PubMedCrossRef
126.
Zurück zum Zitat Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161(10):1798–1805PubMedCrossRef Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161(10):1798–1805PubMedCrossRef
127.
Zurück zum Zitat Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385(6617):634–636PubMedCrossRef Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385(6617):634–636PubMedCrossRef
128.
Zurück zum Zitat Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22(9):3708–3719PubMed Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22(9):3708–3719PubMed
129.
Zurück zum Zitat Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159(5):761–767PubMedCrossRef Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159(5):761–767PubMedCrossRef
130.
Zurück zum Zitat Nolte S, Wong D, Lachford G (2004) Amphetamines for schizophrenia. Cochrane Database Syst Rev 18(4):CD004964 Nolte S, Wong D, Lachford G (2004) Amphetamines for schizophrenia. Cochrane Database Syst Rev 18(4):CD004964
131.
Zurück zum Zitat Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378(6553):180–182PubMedCrossRef Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378(6553):180–182PubMedCrossRef
132.
Zurück zum Zitat Pogarell O, Koch W, Karch S, Dehning S, Muller N, Tatsch K, Poepperl G, Moller HJ (2012) Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry 45(Suppl 1):S36–S41PubMed Pogarell O, Koch W, Karch S, Dehning S, Muller N, Tatsch K, Poepperl G, Moller HJ (2012) Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry 45(Suppl 1):S36–S41PubMed
133.
Zurück zum Zitat Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG (2001) Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25(5):642–650PubMedCrossRef Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG (2001) Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25(5):642–650PubMedCrossRef
134.
Zurück zum Zitat Voruganti LN, Awad AG (2006) Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia–findings from an in vivo SPECT study. Schizophr Res 88(1–3):179–186PubMedCrossRef Voruganti LN, Awad AG (2006) Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia–findings from an in vivo SPECT study. Schizophr Res 88(1–3):179–186PubMedCrossRef
135.
Zurück zum Zitat Heinz A (2002) Dopaminergic dysfunction in alcoholism and schizophrenia–psychopathological and behavioral correlates. Eur Psychiatry 17(1):9–16PubMedCrossRef Heinz A (2002) Dopaminergic dysfunction in alcoholism and schizophrenia–psychopathological and behavioral correlates. Eur Psychiatry 17(1):9–16PubMedCrossRef
136.
Zurück zum Zitat Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160(1):13–23PubMedCrossRef Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160(1):13–23PubMedCrossRef
137.
Zurück zum Zitat Menon M, Mizrahi R, Kapur S (2008) ‘Jumping to conclusions’ and delusions in psychosis: relationship and response to treatment. Schizophr Res ch 98(1–3):225–231CrossRef Menon M, Mizrahi R, Kapur S (2008) ‘Jumping to conclusions’ and delusions in psychosis: relationship and response to treatment. Schizophr Res ch 98(1–3):225–231CrossRef
138.
Zurück zum Zitat Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74(1):1–58PubMedCrossRef Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74(1):1–58PubMedCrossRef
139.
Zurück zum Zitat Roiser JP, Stephan KE, den Ouden HE, Barnes TR, Friston KJ, Joyce EM (2009) Do patients with schizophrenia exhibit aberrant salience? Psychol Med 39(2):199–209PubMedCentralPubMedCrossRef Roiser JP, Stephan KE, den Ouden HE, Barnes TR, Friston KJ, Joyce EM (2009) Do patients with schizophrenia exhibit aberrant salience? Psychol Med 39(2):199–209PubMedCentralPubMedCrossRef
140.
Zurück zum Zitat Strauss GP, Waltz JA, Gold JM (2014) A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 40(Suppl 2):S107–S116PubMedCentralPubMedCrossRef Strauss GP, Waltz JA, Gold JM (2014) A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 40(Suppl 2):S107–S116PubMedCentralPubMedCrossRef
141.
Zurück zum Zitat Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M (1994) A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 36(4):230–236PubMedCrossRef Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M (1994) A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 36(4):230–236PubMedCrossRef
142.
Zurück zum Zitat Thibaut F, Ribeyre JM, Dourmap N, Menard JF, Dollfus S, Petit M (1998) Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 43(1):24–30PubMedCrossRef Thibaut F, Ribeyre JM, Dourmap N, Menard JF, Dollfus S, Petit M (1998) Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 43(1):24–30PubMedCrossRef
143.
Zurück zum Zitat Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinoshita N, Shintani F, Yagi G, Asai M (1995) Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 38(1):50–56PubMedCrossRef Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinoshita N, Shintani F, Yagi G, Asai M (1995) Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 38(1):50–56PubMedCrossRef
144.
Zurück zum Zitat Carpenter WT Jr, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E (2000) Mazindol treatment of negative symptoms. Neuropsychopharmacology 23(4):365–374PubMedCrossRef Carpenter WT Jr, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E (2000) Mazindol treatment of negative symptoms. Neuropsychopharmacology 23(4):365–374PubMedCrossRef
145.
Zurück zum Zitat Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO (2005) Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 162(2):388–390PubMedCrossRef Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO (2005) Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 162(2):388–390PubMedCrossRef
146.
Zurück zum Zitat Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, William Z, Potter WZ (1990) Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 47(7):641–648PubMedCrossRef Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, William Z, Potter WZ (1990) Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 47(7):641–648PubMedCrossRef
147.
Zurück zum Zitat Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB (2002) Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59(6):514–520PubMedCrossRef Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB (2002) Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59(6):514–520PubMedCrossRef
148.
Zurück zum Zitat Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y (2004) Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55(5):439–444PubMedCrossRef Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y (2004) Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55(5):439–444PubMedCrossRef
149.
Zurück zum Zitat Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2006) Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology 189(2):155–164PubMedCrossRef Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2006) Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology 189(2):155–164PubMedCrossRef
150.
Zurück zum Zitat Severance EG, Yolken RH (2008) Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav 7(1):37–45PubMed Severance EG, Yolken RH (2008) Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav 7(1):37–45PubMed
151.
Zurück zum Zitat Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165(8):1033–1039PubMedCrossRef Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165(8):1033–1039PubMedCrossRef
152.
Zurück zum Zitat Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14(11):1017–1023PubMedCrossRef Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14(11):1017–1023PubMedCrossRef
153.
Zurück zum Zitat Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393(1–3):295–314PubMedCrossRef Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393(1–3):295–314PubMedCrossRef
154.
Zurück zum Zitat Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004) Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29(2):259–268PubMedCrossRef Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004) Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29(2):259–268PubMedCrossRef
155.
Zurück zum Zitat Ziedonis DM, Kosten TR, Glazer WM, Frances RJ (1994) Nicotine dependence and schizophrenia. Hosp Community Psychiatry 45(3):204–206PubMed Ziedonis DM, Kosten TR, Glazer WM, Frances RJ (1994) Nicotine dependence and schizophrenia. Hosp Community Psychiatry 45(3):204–206PubMed
156.
Zurück zum Zitat D’Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M (2012) Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry 72(9):785–794PubMedCrossRef D’Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M (2012) Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry 72(9):785–794PubMedCrossRef
157.
Zurück zum Zitat Luckhaus C, Henning U, Ferrea S, Musso F, Mobascher A, Winterer G (2012) Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms. J Neural Transm 119(5):587–595PubMedCrossRef Luckhaus C, Henning U, Ferrea S, Musso F, Mobascher A, Winterer G (2012) Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms. J Neural Transm 119(5):587–595PubMedCrossRef
158.
Zurück zum Zitat Rabin RA, Sacco KA, George TP (2009) Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 114(1–3):91–97PubMedCentralPubMedCrossRef Rabin RA, Sacco KA, George TP (2009) Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 114(1–3):91–97PubMedCentralPubMedCrossRef
159.
Zurück zum Zitat Woznica AA, Sacco KA, George TP (2009) Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res 112(1–3):86–90PubMedCrossRef Woznica AA, Sacco KA, George TP (2009) Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res 112(1–3):86–90PubMedCrossRef
160.
Zurück zum Zitat Winterer G (2010) Why do patients with schizophrenia smoke? Curr Opin Psychiatry 23(2):112–119PubMedCrossRef Winterer G (2010) Why do patients with schizophrenia smoke? Curr Opin Psychiatry 23(2):112–119PubMedCrossRef
161.
Zurück zum Zitat Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S (2010) Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 40(1–2):185–195PubMedCentralPubMedCrossRef Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S (2010) Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 40(1–2):185–195PubMedCentralPubMedCrossRef
162.
Zurück zum Zitat Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63(6):630–638PubMedCrossRef Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63(6):630–638PubMedCrossRef
163.
Zurück zum Zitat Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165(8):1040–1047PubMedCentralPubMedCrossRef Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165(8):1040–1047PubMedCentralPubMedCrossRef
164.
Zurück zum Zitat Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38(6):968–975PubMedCentralPubMedCrossRef Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38(6):968–975PubMedCentralPubMedCrossRef
165.
Zurück zum Zitat Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9(11):984–997, 979 Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9(11):984–997, 979
166.
Zurück zum Zitat Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108PubMedCrossRef Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108PubMedCrossRef
167.
Zurück zum Zitat Akbarian S, Huang HS (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52(2):293–304PubMedCrossRef Akbarian S, Huang HS (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52(2):293–304PubMedCrossRef
168.
Zurück zum Zitat Eyles DW, McGrath JJ, Reynolds GP (2002) Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 57(1):27–34PubMedCrossRef Eyles DW, McGrath JJ, Reynolds GP (2002) Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 57(1):27–34PubMedCrossRef
169.
Zurück zum Zitat Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301–1308PubMedCrossRef Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301–1308PubMedCrossRef
170.
Zurück zum Zitat Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296(5568):692–695PubMedCrossRef Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296(5568):692–695PubMedCrossRef
171.
Zurück zum Zitat Krystal JH, Abi-Saab W, Perry E, D’Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179(1):303–309PubMedCrossRef Krystal JH, Abi-Saab W, Perry E, D’Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179(1):303–309PubMedCrossRef
172.
Zurück zum Zitat Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27(43):11496–11500PubMedCentralPubMedCrossRef Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27(43):11496–11500PubMedCentralPubMedCrossRef
173.
Zurück zum Zitat Moghaddam B, Krystal JH (2012) Capturing the angel in “angel dust”: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 38(5):942–949PubMedCentralPubMedCrossRef Moghaddam B, Krystal JH (2012) Capturing the angel in “angel dust”: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 38(5):942–949PubMedCentralPubMedCrossRef
174.
175.
Zurück zum Zitat Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927PubMed Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927PubMed
176.
Zurück zum Zitat Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37(1):4–15PubMedCentralPubMedCrossRef Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37(1):4–15PubMedCentralPubMedCrossRef
177.
Zurück zum Zitat Stahl SM (2007) Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 12(4):265–268PubMed Stahl SM (2007) Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 12(4):265–268PubMed
178.
Zurück zum Zitat Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13(1):76–83PubMedCentralPubMedCrossRef Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13(1):76–83PubMedCentralPubMedCrossRef
179.
180.
Zurück zum Zitat Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37(11):2515–2521PubMedCentralPubMedCrossRef Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37(11):2515–2521PubMedCentralPubMedCrossRef
181.
Zurück zum Zitat Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, Knowlton RC, den Hollander JA, Lahti AC (2010) Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68(7):625–633PubMedCentralPubMedCrossRef Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, Knowlton RC, den Hollander JA, Lahti AC (2010) Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68(7):625–633PubMedCentralPubMedCrossRef
182.
Zurück zum Zitat Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S (2011) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 69(1):19–27PubMedCentralPubMedCrossRef Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S (2011) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 69(1):19–27PubMedCentralPubMedCrossRef
183.
Zurück zum Zitat Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, Holcomb HH, Barker PB (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39(5):1096–1104PubMedCentralPubMedCrossRef Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, Holcomb HH, Barker PB (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39(5):1096–1104PubMedCentralPubMedCrossRef
184.
Zurück zum Zitat Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69(5):449–459PubMedCrossRef Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69(5):449–459PubMedCrossRef
185.
Zurück zum Zitat Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC (2013) Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res 147(2–3):348–354PubMedCentralPubMedCrossRef Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC (2013) Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res 147(2–3):348–354PubMedCentralPubMedCrossRef
186.
Zurück zum Zitat Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7(1):1–8PubMedCrossRef Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7(1):1–8PubMedCrossRef
187.
Zurück zum Zitat Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738–1740PubMedCrossRef Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738–1740PubMedCrossRef
188.
Zurück zum Zitat Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72(2–3):225–234PubMedCrossRef Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72(2–3):225–234PubMedCrossRef
189.
Zurück zum Zitat Diaz P, Bhaskara S, Dursun SM, Deakin B (2005) Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 25(3):277–278PubMedCrossRef Diaz P, Bhaskara S, Dursun SM, Deakin B (2005) Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 25(3):277–278PubMedCrossRef
190.
Zurück zum Zitat Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA (2013) Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem 13(1):26–54PubMedCentralPubMedCrossRef Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA (2013) Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem 13(1):26–54PubMedCentralPubMedCrossRef
191.
Zurück zum Zitat Profaci CP, Krolikowski KA, Olszewski RT, Neale JH (2011) Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology 216(2):235–243PubMedCentralPubMedCrossRef Profaci CP, Krolikowski KA, Olszewski RT, Neale JH (2011) Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology 216(2):235–243PubMedCentralPubMedCrossRef
192.
Zurück zum Zitat Wischhof L, Aho HE, Koch M (2012) DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation. Pharmacol Biochem Behav 102(1):6–12PubMedCrossRef Wischhof L, Aho HE, Koch M (2012) DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation. Pharmacol Biochem Behav 102(1):6–12PubMedCrossRef
193.
Zurück zum Zitat Inta D, Vogt MA, Perreau-Lenz S, Schneider M, Pfeiffer N, Wojcik SM, Spanagel R, Gass P (2012) Sensorimotor gating, working and social memory deficits in mice with reduced expression of the vesicular glutamate transporter VGLUT1. Behav Brain Res 228(2):328–332PubMedCrossRef Inta D, Vogt MA, Perreau-Lenz S, Schneider M, Pfeiffer N, Wojcik SM, Spanagel R, Gass P (2012) Sensorimotor gating, working and social memory deficits in mice with reduced expression of the vesicular glutamate transporter VGLUT1. Behav Brain Res 228(2):328–332PubMedCrossRef
194.
Zurück zum Zitat Wang ZR, Tan YL, Yang FD, Zhang WF, Zou YZ, Tan SP, Song CS, Li YL, Zhang WH, Zhou DF (2013) Impaired prepulse inhibition of acoustic startle in Chinese patients with first-episode, medication-naive schizophrenia. Chin Med J (Engl) 126(3):526–531 Wang ZR, Tan YL, Yang FD, Zhang WF, Zou YZ, Tan SP, Song CS, Li YL, Zhang WH, Zhou DF (2013) Impaired prepulse inhibition of acoustic startle in Chinese patients with first-episode, medication-naive schizophrenia. Chin Med J (Engl) 126(3):526–531
195.
Zurück zum Zitat Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL (2014) Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res 152(2–3):503–512PubMedCentralPubMedCrossRef Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL (2014) Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res 152(2–3):503–512PubMedCentralPubMedCrossRef
196.
Zurück zum Zitat Ludewig K, Vollenweider FX (2002) Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Med Wkly 132(13–14):159–165PubMed Ludewig K, Vollenweider FX (2002) Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Med Wkly 132(13–14):159–165PubMed
197.
Zurück zum Zitat Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31(5):234–242PubMedCentralPubMedCrossRef Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31(5):234–242PubMedCentralPubMedCrossRef
198.
Zurück zum Zitat Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H (2010) Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77(3):317–326PubMedCrossRef Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H (2010) Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77(3):317–326PubMedCrossRef
199.
Zurück zum Zitat Minoretti P, Politi P, Coen E, Di Vito C, Bertona M, Bianchi M, Emanuele E (2006) The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397(1–2):159–163PubMedCrossRef Minoretti P, Politi P, Coen E, Di Vito C, Bertona M, Bianchi M, Emanuele E (2006) The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397(1–2):159–163PubMedCrossRef
200.
Zurück zum Zitat Wonodi I, Mitchell BD, Stine OC, Hong LE, Elliott A, Kirkpatrick B, Carpenter WT Jr, Thaker GK, Buchanan RW (2006) Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct 2:42PubMedCentralPubMedCrossRef Wonodi I, Mitchell BD, Stine OC, Hong LE, Elliott A, Kirkpatrick B, Carpenter WT Jr, Thaker GK, Buchanan RW (2006) Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct 2:42PubMedCentralPubMedCrossRef
201.
Zurück zum Zitat Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ (2007) The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 6(2):113–119PubMedCrossRef Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ (2007) The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 6(2):113–119PubMedCrossRef
202.
Zurück zum Zitat Wessman J, Paunio T, Tuulio-Henriksson A, Koivisto M, Partonen T, Suvisaari J, Turunen JA, Wedenoja J, Hennah W, Pietilainen OP, Lonnqvist J, Mannila H, Peltonen L (2009) Mixture model clustering of phenotype features reveals evidence for association of DTNBP1 to a specific subtype of schizophrenia. Biol Psychiatry 66(11):990–996PubMedCrossRef Wessman J, Paunio T, Tuulio-Henriksson A, Koivisto M, Partonen T, Suvisaari J, Turunen JA, Wedenoja J, Hennah W, Pietilainen OP, Lonnqvist J, Mannila H, Peltonen L (2009) Mixture model clustering of phenotype features reveals evidence for association of DTNBP1 to a specific subtype of schizophrenia. Biol Psychiatry 66(11):990–996PubMedCrossRef
203.
Zurück zum Zitat Pelka-Wysiecka J, Wronski M, Jasiewicz A, Grzywacz A, Tybura P, Kucharska-Mazur J, Bienkowski P, Samochowiec J (2013) BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. Pharmacol Rep 65(5):1185–1193PubMedCrossRef Pelka-Wysiecka J, Wronski M, Jasiewicz A, Grzywacz A, Tybura P, Kucharska-Mazur J, Bienkowski P, Samochowiec J (2013) BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. Pharmacol Rep 65(5):1185–1193PubMedCrossRef
204.
Zurück zum Zitat Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O’Neill FA, Walsh D, Kendler KS (2005) Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 162(10):1824–1832PubMedCrossRef Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O’Neill FA, Walsh D, Kendler KS (2005) Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 162(10):1824–1832PubMedCrossRef
205.
Zurück zum Zitat DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK (2006) Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 163(3):532–534PubMedCrossRef DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK (2006) Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 163(3):532–534PubMedCrossRef
206.
Zurück zum Zitat Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, Kuhn KU, Maier W, Wagner M, Kumari V (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 35(7):1429–1439PubMedCentralPubMedCrossRef Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, Kuhn KU, Maier W, Wagner M, Kumari V (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 35(7):1429–1439PubMedCentralPubMedCrossRef
207.
Zurück zum Zitat Zahari Z, Teh LK, Ismail R, Razali SM (2011) Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia. Psychiatr Genet 21(4):183–189PubMedCrossRef Zahari Z, Teh LK, Ismail R, Razali SM (2011) Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia. Psychiatr Genet 21(4):183–189PubMedCrossRef
208.
Zurück zum Zitat Itokawa M, Arinami T, Toru M (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. J Pharmacol Sci 114(1):1–5PubMedCrossRef Itokawa M, Arinami T, Toru M (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. J Pharmacol Sci 114(1):1–5PubMedCrossRef
209.
Zurück zum Zitat Park HJ, Kim JW, Lee SK, Kim SK, Park JK, Cho AR, Chung JH, Song JY (2011) Association between the SLC6A12 gene and negative symptoms of schizophrenia in a Korean population. Psychiatry Res 189(3):478–479PubMedCrossRef Park HJ, Kim JW, Lee SK, Kim SK, Park JK, Cho AR, Chung JH, Song JY (2011) Association between the SLC6A12 gene and negative symptoms of schizophrenia in a Korean population. Psychiatry Res 189(3):478–479PubMedCrossRef
210.
Zurück zum Zitat Pelayo-Teran JM, Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, Mata I, Arranz MJ, Leyva-Cobian F, Vazquez-Barquero JL (2008) Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am J Med Genet B Neuropsychiatr Genet 147B(5):550–556PubMedCrossRef Pelayo-Teran JM, Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, Mata I, Arranz MJ, Leyva-Cobian F, Vazquez-Barquero JL (2008) Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am J Med Genet B Neuropsychiatr Genet 147B(5):550–556PubMedCrossRef
211.
Zurück zum Zitat Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Bourgon J, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B (2011) Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res 185(1–2):286–289PubMedCrossRef Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Bourgon J, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B (2011) Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res 185(1–2):286–289PubMedCrossRef
212.
Zurück zum Zitat Wang Y, Fang Y, Shen Y, Xu Q (2010) Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res 179(2):147–150PubMedCrossRef Wang Y, Fang Y, Shen Y, Xu Q (2010) Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res 179(2):147–150PubMedCrossRef
213.
Zurück zum Zitat McClay JL, Fanous A, van den Oord EJ, Webb BT, Walsh D, O’Neill FA, Kendler KS, Chen X (2006) Catechol-O-methyltransferase and the clinical features of psychosis. Am J Med Genet B Neuropsychiatr Genet 141B(8):935–938PubMedCrossRef McClay JL, Fanous A, van den Oord EJ, Webb BT, Walsh D, O’Neill FA, Kendler KS, Chen X (2006) Catechol-O-methyltransferase and the clinical features of psychosis. Am J Med Genet B Neuropsychiatr Genet 141B(8):935–938PubMedCrossRef
214.
Zurück zum Zitat Molero P, Ortuno F, Zalacain M, Patino-Garcia A (2007) Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7(6):418–426PubMedCrossRef Molero P, Ortuno F, Zalacain M, Patino-Garcia A (2007) Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7(6):418–426PubMedCrossRef
215.
Zurück zum Zitat Schurhoff F, Szoke A, Chevalier F, Roy I, Meary A, Bellivier F, Giros B, Leboyer M (2007) Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. Am J Med Genet B Neuropsychiatr Genet 144B(1):64–68PubMedCrossRef Schurhoff F, Szoke A, Chevalier F, Roy I, Meary A, Bellivier F, Giros B, Leboyer M (2007) Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. Am J Med Genet B Neuropsychiatr Genet 144B(1):64–68PubMedCrossRef
216.
Zurück zum Zitat Chen CY, Lu RB, Yeh YW, Shih MC, Huang SY (2011) Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese. Genes Brain Behav 10(3):316–324PubMedCrossRef Chen CY, Lu RB, Yeh YW, Shih MC, Huang SY (2011) Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese. Genes Brain Behav 10(3):316–324PubMedCrossRef
217.
Zurück zum Zitat Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY (2012) Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 159B(4):370–375PubMedCrossRef Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY (2012) Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 159B(4):370–375PubMedCrossRef
218.
Zurück zum Zitat Wright GE, Niehaus DJ, van der Merwe L, Koen L, Korkie LJ, Kinnear CJ, Drogemoller BI, Warnich L (2012) Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Prog Neuropsychopharmacol Biol Psychiatry 39(1):163–169PubMedCrossRef Wright GE, Niehaus DJ, van der Merwe L, Koen L, Korkie LJ, Kinnear CJ, Drogemoller BI, Warnich L (2012) Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Prog Neuropsychopharmacol Biol Psychiatry 39(1):163–169PubMedCrossRef
219.
Zurück zum Zitat Schneider M, Van der Linden M, Glaser B, Rizzi E, Dahoun SP, Hinard C, Bartoloni L, Antonarakis SE, Debbane M, Eliez S (2012) Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome. Psychiatry Res 196(2–3):277–284PubMedCrossRef Schneider M, Van der Linden M, Glaser B, Rizzi E, Dahoun SP, Hinard C, Bartoloni L, Antonarakis SE, Debbane M, Eliez S (2012) Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome. Psychiatry Res 196(2–3):277–284PubMedCrossRef
220.
Zurück zum Zitat Kang WS, Park JK, Park HJ, Kim SK, Cho AR, Lee SM, Kim JW, Song JY (2012) Association between catechol-O-methyltransferase Val158Met polymorphism and negative symptoms of schizophrenia in the Korean population. Psychiatry Res 198(2):338–339PubMedCrossRef Kang WS, Park JK, Park HJ, Kim SK, Cho AR, Lee SM, Kim JW, Song JY (2012) Association between catechol-O-methyltransferase Val158Met polymorphism and negative symptoms of schizophrenia in the Korean population. Psychiatry Res 198(2):338–339PubMedCrossRef
221.
Zurück zum Zitat Docherty AR, Sponheim SR (2008) Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. J Abnorm Psychol 117(4):788–798PubMedCentralPubMedCrossRef Docherty AR, Sponheim SR (2008) Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. J Abnorm Psychol 117(4):788–798PubMedCentralPubMedCrossRef
222.
Zurück zum Zitat Tomppo L, Hennah W, Miettunen J, Jarvelin MR, Veijola J, Ripatti S, Lahermo P, Lichtermann D, Peltonen L, Ekelund J (2009) Association of variants in DISC1 with psychosis-related traits in a large population cohort. Arch Gen Psychiatry 66(2):134–141PubMedCentralPubMedCrossRef Tomppo L, Hennah W, Miettunen J, Jarvelin MR, Veijola J, Ripatti S, Lahermo P, Lichtermann D, Peltonen L, Ekelund J (2009) Association of variants in DISC1 with psychosis-related traits in a large population cohort. Arch Gen Psychiatry 66(2):134–141PubMedCentralPubMedCrossRef
223.
Zurück zum Zitat Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M (2005) Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52(2):83–89PubMedCrossRef Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M (2005) Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52(2):83–89PubMedCrossRef
224.
Zurück zum Zitat Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M (2005) COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr Res 73(1):27–30PubMedCrossRef Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M (2005) COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr Res 73(1):27–30PubMedCrossRef
225.
Zurück zum Zitat Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A (2000) Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 57(5):471–480PubMedCrossRef Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A (2000) Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 57(5):471–480PubMedCrossRef
226.
Zurück zum Zitat Wolkin A, Choi SJ, Szilagyi S, Sanfilipo M, Rotrosen JP, Lim KO (2003) Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am J Psychiatry 160(3):572–574PubMedCrossRef Wolkin A, Choi SJ, Szilagyi S, Sanfilipo M, Rotrosen JP, Lim KO (2003) Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am J Psychiatry 160(3):572–574PubMedCrossRef
227.
Zurück zum Zitat Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 5:976–984CrossRef Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 5:976–984CrossRef
Metadaten
Titel
Neurobiological background of negative symptoms
verfasst von
Silvana Galderisi
Eleonora Merlotti
Armida Mucci
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 7/2015
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-015-0590-4

Weitere Artikel der Ausgabe 7/2015

European Archives of Psychiatry and Clinical Neuroscience 7/2015 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.